MYC is a target of the Wnt signalling pathway and governs numerous cellular and developmental programmes hijacked in cancers. The amplification of MYC is a frequently occurring genetic alteration in cancer genomes, and this transcription factor is implicated in metabolic reprogramming, cell death, and angiogenesis in cancers. In this review, we analyse MYC gene networks in solid cancers. We investigate the interaction of MYC with long non-coding RNAs (lncRNAs). Furthermore, we investigate the role of MYC regulatory networks in inducing changes to cellular processes, including autophagy and mitophagy. Finally, we review the interaction and mutual regulation between MYC and lncRNAs, and autophagic processes and analyse these networks as unexplored areas of targeting and manipulation for therapeutic gain in MYC-driven malignancies.

CEITEC Masaryk University 625 00 Brno Czech Republic

Department of Functional Genomics GlaxoSmithKline Stevenage SG1 2NY UK

Department of Life Sciences Birmingham City University Birmingham B15 3TN UK

Department of Neurology Massachusetts General Hospital Harvard Medical School Boston MA 02114 USA

Division of Cellular and Molecular Pathology Department of Pathology University of Cambridge Cambridge CB2 0QQ UK

Institute of Cancer and Genomic Sciences College of Medical and Dental Sciences University of Birmingham Birmingham B15 2SY UK

Institute of Translational Medicine University Hospitals Birmingham NHS Foundation Trust Birmingham B15 2TH UK

Mammalian Genetics Unit Medical Research Council Harwell Institute Oxfordshire OX11 0RD UK

MRC Health Data Research Birmingham B15 2TT UK

NIHR Biomedical Research Centre Birmingham B15 2TT UK

NIHR Experimental Cancer Medicine Centre Birmingham B15 2TT UK

NIHR Surgical Reconstruction and Microbiology Research Centre Birmingham B15 2TT UK

Zobrazit více v PubMed

Malynn B.A., de Alboran I.M., O’Hagan R.C., Bronson R., Davidson L., DePinho R.A., Alt F.W. N-myc can functionally replace c-myc in murine development, cellular growth, and differentiation. Genes Dev. 2000;14:1390–1399. PubMed PMC

Kohl N.E., Kanda N., Schreck R.R., Bruns G., Latt S.A., Gilbert F., Alt F.W. Transposition and amplification of oncogene-related sequences in human neuroblastomas. Cell. 1983;35:359–367. doi: 10.1016/0092-8674(83)90169-1. PubMed DOI

Amati B., Littlewood T.D., Evan G.I., Land H. The c-Myc protein induces cell cycle progression and apoptosis through dimerization with Max. EMBO J. 1993;12:5083–5087. doi: 10.1002/j.1460-2075.1993.tb06202.x. PubMed DOI PMC

Dang C.V. MYC on the path to cancer. Cell. 2012;149:22–35. doi: 10.1016/j.cell.2012.03.003. PubMed DOI PMC

Soucek L., Evan G.I. The ups and downs of Myc biology. Curr. Opin. Genet. Dev. 2010;20:91–95. doi: 10.1016/j.gde.2009.11.001. PubMed DOI PMC

Kelly K., Cochran B.H., Stiles C.D., Leder P. Cell-specific regulation of the c-myc gene by lymphocyte mitogens and platelet-derived growth factor. Cell. 1983;35:603–610. doi: 10.1016/0092-8674(83)90092-2. PubMed DOI

Satoh K., Yachida S., Sugimoto M., Oshima M., Nakagawa T., Akamoto S., Tabata S., Saitoh K., Kato K., Sato S., et al. Global metabolic reprogramming of colorectal cancer occurs at adenoma stage and is induced by MYC. Proc. Natl. Acad. Sci. USA. 2017;114:E7697–E7706. doi: 10.1073/pnas.1710366114. PubMed DOI PMC

Adams J.M., Harris A.W., Pinkert C.A., Corcoran L.M., Alexander W.S., Cory S., Palmiter R.D., Brinster R.L. The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice. Nature. 1985;318:533–538. doi: 10.1038/318533a0. PubMed DOI

Stine Z.E., Walton Z.E., Altman B.J., Hsieh A.L., Dang C.V. MYC, metabolism, and cancer. Cancer Discov. 2015;5:1024–1039. doi: 10.1158/2159-8290.CD-15-0507. PubMed DOI PMC

He T.-C., Sparks A.B., Rago C., Hermeking H., Zawel L., da Costa L.T., Morin P.J., Vogelstein B., Kinzler K.W. Identification of c-MYC as a target of the APC pathway. Science. 1998;281:1509–1512. doi: 10.1126/science.281.5382.1509. PubMed DOI

Palomero T., Lim W.K., Odom D.T., Sulis M.L., Real P.J., Margolin A., Barnes K.C., O’Neil J., Neuberg D., Weng A.P., et al. NOTCH1 directly regulates c-MYC and activates a feed-forward-loop transcriptional network promoting leukemic cell growth. Proc. Natl. Acad. Sci. USA. 2006;103:18261–18266. doi: 10.1073/pnas.0606108103. PubMed DOI PMC

Swartling F.J., Savov V., Persson A.I., Chen J., Hackett C.S., Northcott P.A., Grimmer M.R., Lau J., Chesler L., Perry A., et al. Distinct neural stem cell populations give rise to disparate brain tumors in response to N-MYC. Cancer Cell. 2012;21:601–613. doi: 10.1016/j.ccr.2012.04.012. PubMed DOI PMC

Evan G.I., Littlewood T.D. The role of c-myc in cell growth. Curr. Opin. Genet. Dev. 1993;3:44–49. doi: 10.1016/S0959-437X(05)80339-9. PubMed DOI

Ayer D.E., Eisenman R.N. A switch from Myc:Max to Mad:Max heterocomplexes accompanies monocyte/macrophage differentiation. Genes Dev. 1993;7:2110–2119. doi: 10.1101/gad.7.11.2110. PubMed DOI

Laurenti E., Varnum-Finney B., Wilson A., Ferrero I., Blanco-Bose W.E., Ehninger A., Knoepfler P.S., Cheng P.F., MacDonald H.R., Eisenman R.N., et al. Hematopoietic stem cell function and survival depend on c-Myc and N-Myc activity. Cell Stem Cell. 2008;3:611–624. doi: 10.1016/j.stem.2008.09.005. PubMed DOI PMC

Gandarillas A., Watt F. c-Myc promotes differentiation of human epidermal stem cells. Genes Dev. 1997;11:2869–2882. doi: 10.1101/gad.11.21.2869. PubMed DOI PMC

Land H., Parada L.F., Weinberg R.A. Tumorigenic conversion of primary embryo fibroblasts requires at least two cooperating oncogenes. Nature. 1983;304:596–602. doi: 10.1038/304596a0. PubMed DOI

Mathew P., Valentine M.B., Bowman L.C., Rowe S.T., Nash M.B., Valentine V.A., Cohn S.L., Castleberry R.P., Brodeur G.M., Look A.T. Detection of MYCN gene amplification in neuroblastoma by fluorescence in situ hybridization: A pediatric oncology group study. Neoplasia. 2001;3:105–109. doi: 10.1038/sj.neo.7900146. PubMed DOI PMC

Davis F.G., McCarthy B.J., Freels S., Kupelian V., Bondy M.L. The conditional probability of survival of patients with primary malignant brain tumors: Surveillance, epidemiology, and end results (SEER) data. Cancer. 1999;85:485–491. doi: 10.1002/(SICI)1097-0142(19990115)85:2<485::AID-CNCR29>3.0.CO;2-L. PubMed DOI

Dang C.V. MYC, metabolism, cell growth, and tumorigenesis. Cold Spring Harb. Perspect. Med. 2013;3:a014217. doi: 10.1101/cshperspect.a014217. PubMed DOI PMC

Sodir N.M., Swigart L.B., Karnezis A.N., Hanahan D., Evan G.I., Soucek L. Endogenous Myc maintains the tumor microenvironment. Genes Dev. 2011;25:907–916. doi: 10.1101/gad.2038411. PubMed DOI PMC

Rapp U.R., Korn C., Ceteci F., Karreman C., Luetkenhaus K., Serafin V., Zanucco E., Castro I., Potapenko T. MYC is a metastasis gene for non-small-cell lung cancer. PLoS ONE. 2009;4:e6029. doi: 10.1371/journal.pone.0006029. PubMed DOI PMC

Shchors K., Shchors E., Rostker F., Lawlor E.R., Brown-Swigart L., Evan G.I. The Myc-dependent angiogenic switch in tumors is mediated by interleukin 1beta. Genes Dev. 2006;20:2527–2538. doi: 10.1101/gad.1455706. PubMed DOI PMC

Berger A., Brady N.J., Bareja R., Robinson B., Conteduca V., Augello M.A., Puca L., Ahmed A., Dardenne E., Lu X., et al. N-Myc-mediated epigenetic reprogramming drives lineage plasticity in advanced prostate cancer. J. Clin. Invest. 2019;129:3924–3940. doi: 10.1172/JCI127961. PubMed DOI PMC

Murakami S., Nemazanyy I., White S.M., Chen H., Nguyen C.D.K., Graham G.T., Saur D., Pende M., Yi C. A Yap-Myc-Sox2-p53 Regulatory Network Dictates Metabolic Homeostasis and Differentiation in Kras-Driven Pancreatic Ductal Adenocarcinomas. Dev. Cell. 2019;51:113–128.e9. doi: 10.1016/j.devcel.2019.07.022. PubMed DOI PMC

Tao R., Murad N., Xu Z., Zhang P., Okonechnikov K., Kool M., Rivero-Hinojosa S., Lazarski C., Zheng P., Liu Y., et al. MYC Drives Group 3 Medulloblastoma through Transformation of Sox2+ Astrocyte Progenitor Cells. Cancer Res. 2019;79:1967–1980. doi: 10.1158/0008-5472.CAN-18-1787. PubMed DOI PMC

Wang Y., Gao S., Wang W., Xia Y., Liang J. Downregulation of N-Myc inhibits neuroblastoma cell growth via the Wnt/β-catenin signaling pathway. Mol. Med. Rep. 2018;18:377–384. doi: 10.3892/mmr.2018.8966. PubMed DOI

Ooi C.Y., Carter D.R., Liu B., Mayoh C., Beckers A., Lalwani A., Nagy Z., De Brouwer S., Decaesteker B., Hung T.T., et al. Network Modeling of microRNA-mRNA Interactions in Neuroblastoma Tumorigenesis Identifies miR-204 as a Direct Inhibitor of MYCN. Cancer Res. 2018;78:3122–3134. doi: 10.1158/0008-5472.CAN-17-3034. PubMed DOI

Pandey P.R., Chatterjee B., Olanich M.E., Khan J., Miettinen M.M., Hewitt S.M., Barr F.G. PAX3-FOXO1 is essential for tumour initiation and maintenance but not recurrence in a human myoblast model of rhabdomyosarcoma. J. Pathol. 2017;241:626–637. doi: 10.1002/path.4867. PubMed DOI PMC

Kortlever R.M., Sodir N.M., Wilson C.H., Burkhart D.L., Pellegrinet L., Brown Swigart L., Littlewood T.D., Evan G.I. Myc Cooperates with Ras by Programming Inflammation and Immune Suppression. Cell. 2017;171:1301–1315.e14. doi: 10.1016/j.cell.2017.11.013. PubMed DOI PMC

Soucek L., Whitfield J., Martins C.P., Finch A.J., Murphy D.J., Sodir N.M., Karnezis A.N., Swigart L.B., Nasi S., Evan G.I. Modelling Myc inhibition as a cancer therapy. Nature. 2008;455:679–683. doi: 10.1038/nature07260. PubMed DOI PMC

Ye M., Dong S., Hou H., Zhang T., Shen M. Oncogenic Role of Long Noncoding RNAMALAT1 in Thyroid Cancer Progression through Regulation of the miR-204/IGF2BP2/m6A-MYC Signaling. Mol. Ther. Nucleic Acids. 2020;23:1–12. doi: 10.1016/j.omtn.2020.09.023. PubMed DOI PMC

Crea F., Venalainen E., Ci X., Cheng H., Pikor L., Parolia A., Xue H., Nur Saidy N.R., Lin D., Lam W., et al. The role of epigenetics and long noncoding RNA MIAT in neuroendocrine prostate cancer. Epigenomics. 2016;8:721–731. doi: 10.2217/epi.16.6. PubMed DOI

Gargini R., García-Escudero V., Izquierdo M., Wandosell F. Oncogene-mediated tumor transformation sensitizes cells to autophagy induction. Oncol. Rep. 2016;35:3689–3695. doi: 10.3892/or.2016.4699. PubMed DOI

García-Escudero V., Gargini R. Autophagy induction as an efficient strategy to eradicate tumors. Autophagy. 2008;4:923–925. doi: 10.4161/auto.6714. PubMed DOI

Gargini R., García-Escudero V., Izquierdo M. Therapy mediated by mitophagy abrogates tumor progression. Autophagy. 2011;7:466–476. doi: 10.4161/auto.7.5.14731. PubMed DOI

Ying H., Kimmelman A.C., Lyssiotis C.A., Hua S., Chu G.C., Fletcher-Sananikone E., Locasale J.W., Son J., Zhang H., Coloff J.L., et al. Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism. Cell. 2012;149:656–670. doi: 10.1016/j.cell.2012.01.058. PubMed DOI PMC

Zhang W., Nandakumar N., Shi Y., Manzano M., Smith A., Graham G., Gupta S., Vietsch E.E., Laughlin S.Z., Wadhwa M., et al. Downstream of mutant KRAS, the transcription regulator YAP is essential for neoplastic progression to pancreatic ductal adenocarcinoma. Sci. Signal. 2014;7:ra42. doi: 10.1126/scisignal.2005049. PubMed DOI PMC

Brodeur G.M. Neuroblastoma: Biological insights into a clinical enigma. Nat. Rev. Cancer. 2003;3:203–216. doi: 10.1038/nrc1014. PubMed DOI

Driman D., Thorner P.S., Greenberg M.L., Chilton-MacNeill S., Squire J. MYCN gene amplification in rhabdomyosarcoma. Cancer. 1994;73:2231–2237. doi: 10.1002/1097-0142(19940415)73:8<2231::AID-CNCR2820730832>3.0.CO;2-E. PubMed DOI

Hachitanda Y., Toyoshima S., Akazawa K., Tsuneyoshi M. N-myc gene amplification in rhabdomyosarcoma detected by fluorescence in situ hybridization: Its correlation with histologic features. Mod. Pathol. 1998;11:1222–1227. PubMed

Williamson D., Lu Y.J., Gordon T., Sciot R., Kelsey A., Fisher C., Poremba C., Anderson J., Pritchard-Jones K., Shipley J. Relationship between MYCN copy number and expression in rhabdomyosarcomas and correlation with adverse prognosis in the alveolar subtype. J. Clin. Oncol. 2005;23:880–888. doi: 10.1200/JCO.2005.11.078. PubMed DOI

He J., Li F., Zhou Y., Hou X., Liu S., Li X., Zhang Y., Jing X., Yang L. LncRNA XLOC_006390 promotes pancreatic carcinogenesis and glutamate metabolism by stabilizing c-Myc. Cancer Lett. 2020;469:419–428. doi: 10.1016/j.canlet.2019.11.021. PubMed DOI

Xu Z., Liu C., Zhao Q., Lü J., Ding X., Luo A., He J., Wang G., Li Y., Cai Z., et al. Long non-coding RNA CCAT2 promotes oncogenesis in triple-negative breast cancer by regulating stemness of cancer cells. Pharmacol. Res. 2020;152:104628. doi: 10.1016/j.phrs.2020.104628. PubMed DOI

Wu J., Zhu P., Lu T., Du Y., Wang Y., He L., Ye B., Liu B., Yang L., Wang J., et al. The long non-coding RNA LncHDAC2 drives the self-renewal of liver cancer stem cells via activation of Hedgehog signaling. J. Hepatol. 2019;70:918–929. doi: 10.1016/j.jhep.2018.12.015. PubMed DOI

Crea F., Clermont P.L., Parolia A., Wang Y., Helgason C.D. The non-coding transcriptome as a dynamic regulator of cancer metastasis. Cancer Metastasis Rev. 2014;33:1–16. doi: 10.1007/s10555-013-9455-3. PubMed DOI PMC

Sun L., Su Y., Liu X., Xu M., Chen X., Zhu Y., Guo Z., Bai T., Dong L., Wei C., et al. Serum and exosome long non coding RNAs as potential biomarkers for hepatocellular carcinoma. J. Cancer. 2018;9:2631–2639. doi: 10.7150/jca.24978. PubMed DOI PMC

Conigliaro A., Costa V., Lo Dico A., Saieva L., Buccheri S., Dieli F., Manno M., Raccosta S., Mancone C., Tripodi M., et al. CD90+ liver cancer cells modulate endothelial cell phenotype through the release of exosomes containing H19 lncRNA. Mol. Cancer. 2015;14:155. doi: 10.1186/s12943-015-0426-x. PubMed DOI PMC

Roobol M.J., Schröder F.H., van Leeuwen P., Wolters T., van den Bergh R.C., van Leenders G.J., Hessels D. Performance of the prostate cancer antigen 3 (PCA3) gene and prostate-specific antigen in prescreened men: Exploring the value of PCA3 for a first-line diagnostic test. Eur. Urol. 2010;58:475–481. doi: 10.1016/j.eururo.2010.06.039. PubMed DOI

Bellmunt J., Eigl B.J., Senkus E., Loriot Y., Twardowski P., Castellano D., Blais N., Sridhar S.S., Sternberg C.N., Retz M., et al. Borealis-1: A randomized, first-line, placebo-controlled, phase II study evaluating apatorsen and chemotherapy for patients with advanced urothelial cancer. Ann. Oncol. 2017;28:2481–2488. doi: 10.1093/annonc/mdx400. PubMed DOI

Chi K.N., Higano C.S., Blumenstein B., Ferrero J.M., Reeves J., Feyerabend S., Gravis G., Merseburger A.S., Stenzl A., Bergman A.M., et al. Custirsen in combination with docetaxel and prednisone for patients with metastatic castration-resistant prostate cancer (SYNERGY trial): A phase 3, multicentre, open-label, randomised trial. Lancet Oncol. 2017;18:473–485. doi: 10.1016/S1470-2045(17)30168-7. PubMed DOI

Chery J. RNA therapeutics: RNAi and antisense mechanisms and clinical applications. Postdoc J. 2016;4:35–50. doi: 10.14304/SURYA.JPR.V4N7.5. PubMed DOI PMC

Wang W.T., Han C., Sun Y.M., Chen T.Q., Chen Y.Q. Noncoding RNAs in cancer therapy resistance and targeted drug development. J. Hematol. Oncol. 2019;12:55. doi: 10.1186/s13045-019-0748-z. PubMed DOI PMC

Shen X., Corey D.R. Chemistry, mechanism and clinical status of antisense oligonucleotides and duplex RNAs. Nucleic Acids Res. 2018;46:1584–1600. doi: 10.1093/nar/gkx1239. PubMed DOI PMC

Sekhon H.S., London C.A., Sekhon M., Iversen P.L., Devi G.R. c-MYC antisense phosphosphorodiamidate morpholino oligomer inhibits lung metastasis in a murine tumor model. Lung Cancer. 2008;60:347–354. doi: 10.1016/j.lungcan.2007.10.028. PubMed DOI

Iversen P.L., Arora V., Acker A.J., Mason D.H., Devi G.R. Efficacy of antisense morpholino oligomer targeted to c-myc in prostate cancer xenograft murine model and a Phase I safety study in humans. Clin. Cancer Res. 2003;9:2510–2519. PubMed

Zhang Z., Lin W., Lin Y., Kang M., Zhu J., Tong Z., Wu L., Sun J., Lin J. Long intergenic non-coding RNA Linc00485 promotes lung cancer progression by modulating miR-298/c-Myc axis. J. Cell Mol. Med. 2021;25:309–322. doi: 10.1111/jcmm.16036. PubMed DOI PMC

Liu S., Zheng Y., Zhang Y., Zhang J., Xie F., Guo S., Gu J., Yang J., Zheng P., Lai J., et al. Methylation-mediated LINC00261 suppresses pancreatic cancer progression by epigenetically inhibiting c-Myc transcription. Theranostics. 2020;10:10634–10651. doi: 10.7150/thno.44278. PubMed DOI PMC

Zhang X., Niu W., Mu M., Hu S., Niu C. Long non-coding RNA LPP-AS2 promotes glioma tumorigenesis via miR-7-5p/EGFR/PI3K/AKT/c-MYC feedback loop. J. Exp. Clin. Cancer Res. 2020;39:196. doi: 10.1186/s13046-020-01695-8. PubMed DOI PMC

Li H., Liu J., Cao W., Xiao X., Liang L., Liu-Smith F., Wang W., Liu H., Zhou P., Ouyang R., et al. C-myc/miR-150/EPG5 axis mediated dysfunction of autophagy promotes development of non-small cell lung cancer. Theranostics. 2019;9:5134–5148. doi: 10.7150/thno.34887. PubMed DOI PMC

Cianfanelli V., Fuoco C., Lorente M., Salazar M., Quondamatteo F., Gherardini P.F., De Zio D., Nazio F., Antonioli M., D’Orazio M., et al. AMBRA1 links autophagy to cell proliferation and tumorigenesis by promoting c-Myc dephosphorylation and degradation. Nat. Cell Biol. 2015;17:20–30. doi: 10.1038/ncb3072. PubMed DOI PMC

Hart L.S., Cunningham J.T., Datta T., Dey S., Tameire F., Lehman S.L., Qiu B., Zhang H., Cerniglia G., Bi M., et al. ER stress-mediated autophagy promotes Myc-dependent transformation and tumor growth. J. Clin. Invest. 2012;122:4621–4634. doi: 10.1172/JCI62973. PubMed DOI PMC

Gomes L.R., Menck C.F.M., Cuervo A.M. Chaperone-mediated autophagy prevents cellular transformation by regulating MYC proteasomal degradation. Autophagy. 2017;13:928–940. doi: 10.1080/15548627.2017.1293767. PubMed DOI PMC

Zhai S., Xu Z., Xie J., Zhang J., Wang X., Peng C., Li H., Chen H., Shen B., Deng X. Epigenetic silencing of LncRNA LINC00261 promotes c-myc-mediated aerobic glycolysis by regulating miR-222-3p/HIPK2/ERK axis and sequestering IGF2BP1. Oncogene. 2021;40:277–291. doi: 10.1038/s41388-020-01525-3. PubMed DOI PMC

Shigeyasu K., Toden S., Ozawa T., Matsuyama T., Nagasaka T., Ishikawa T., Sahoo D., Ghosh P., Uetake H., Fujiwara T. The PVT1 lncRNA is a novel epigenetic enhancer of MYC, and a promising risk-stratification biomarker in colorectal cancer. Mol. Cancer. 2020;19:155. doi: 10.1186/s12943-020-01277-4. PubMed DOI PMC

Olivero C.E., Martínez-Terroba E., Zimmer J., Liao C., Tesfaye E., Hooshdaran N., Schofield J.A., Bendor J., Fang D., Simon M.D., et al. p53 Activates the Long Noncoding RNA Pvt1b to Inhibit Myc and Suppress Tumorigenesis. Mol. Cell. 2020;77:761–774.e8. doi: 10.1016/j.molcel.2019.12.014. PubMed DOI PMC

Hu Y., Wang F., Xu F., Fang K., Fang Z., Shuai X., Cai K., Chen J., Hu P., Chen D., et al. A reciprocal feedback of Myc and lncRNA MTSS1-AS contributes to extracellular acidity-promoted metastasis of pancreatic cancer. Theranostics. 2020;10:10120–10140. doi: 10.7150/thno.49147. PubMed DOI PMC

Usman R.M., Razzaq F., Akbar A., Farooqui A.A., Iftikhar A., Latif A., Hassan H., Zhao J., Carew J.S., Nawrocki S.T., et al. Role and mechanism of autophagy-regulating factors in tumorigenesis and drug resistance. Asia. Pac. J. Clin. Oncol. 2021;17:193–208. doi: 10.1111/ajco.13449. PubMed DOI

Toh P.P.C., Luo S., Menzies F.M., Raskó T., Wanker E.E., Rubinsztein D.C. Myc inhibition impairs autophagosome formation. Hum. Mol. Genet. 2013;22:5237–5248. doi: 10.1093/hmg/ddt381. PubMed DOI PMC

Sears R.C. The Life Cycle of C-Myc: From Synthesis to Degradation. Cell Cycle. 2004;3:1131–1135. doi: 10.4161/cc.3.9.1145. PubMed DOI

Mo H., He J., Yuan Z., Wu Z., Liu B., Lin X., Guan J. PLK1 contributes to autophagy by regulating MYC stabilization in osteosarcoma cells. Onco Targets Ther. 2019;12:7527–7536. doi: 10.2147/OTT.S210575. PubMed DOI PMC

Kon M., Kiffin R., Koga H., Chapochnick J., Macian F., Varticovski L., Cuervo A.M. Chaperone-mediated autophagy is required for tumor growth. Sci. Transl. Med. 2011;3:109ra117. doi: 10.1126/scitranslmed.3003182. PubMed DOI PMC

Vara-Perez M., Felipe-Abrio B., Agostinis P. Mitophagy in Cancer: A Tale of Adaptation. Cells. 2019;8:493. doi: 10.3390/cells8050493. PubMed DOI PMC

Zhang C., Nie P., Zhou C., Hu Y., Duan S., Gu M., Jiang D., Wang Y., Deng Z., Chen J., et al. Oxidative stress-induced mitophagy is suppressed by the miR-106b-93-25 cluster in a protective manner. Cell Death Dis. 2021;12:209. doi: 10.1038/s41419-021-03484-3. PubMed DOI PMC

Kim E.H., Choi K.S. A critical role of superoxide anion in selenite-induced mitophagic cell death. Autophagy. 2008;4:76–78. doi: 10.4161/auto.5119. PubMed DOI

Takahashi Y., Hori T., Cooper T.K., Liao J., Desai N., Serfass J.M., Young M.M., Park S., Izu Y., Wang H.-G. Bif-1 haploinsufficiency promotes chromosomal instability and accelerates Myc-driven lymphomagenesis via suppression of mitophagy. Blood. 2013;121:1622–1632. doi: 10.1182/blood-2012-10-459826. PubMed DOI PMC

Pelengaris S., Littlewood T., Khan M., Elia G., Evan G. Reversible activation of c-Myc in skin: Induction of a complex neoplastic phenotype by a single oncogenic lesion. Mol. Cell. 1999;3:565–577. doi: 10.1016/S1097-2765(00)80350-0. PubMed DOI

Bisgrove D.A., Mahmoudi T., Henklein P., Verdin E. Conserved P-TEFb-interacting domain of BRD4 inhibits HIV transcription. Proc. Natl. Acad. Sci. USA. 2007;104:13690–13695. doi: 10.1073/pnas.0705053104. PubMed DOI PMC

Delmore J.E., Issa G.C., Lemieux M.E., Rahl P.B., Shi J., Jacobs H.M., Kastritis E., Gilpatrick T., Paranal R.M., Qi J., et al. BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc. Cell. 2011;146:904–917. doi: 10.1016/j.cell.2011.08.017. PubMed DOI PMC

Wu R., Li L., Bai Y., Yu B., Xie C., Wu H., Zhang Y., Huang L., Yan Y., Li X., et al. The long noncoding RNA LUCAT1 promotes colorectal cancer cell proliferation by antagonizing Nucleolin to regulate MYC expression. Cell Death Dis. 2020;11:908. doi: 10.1038/s41419-020-03095-4. PubMed DOI PMC

Chen Q., Shen H., Zhu X., Liu Y., Yang H., Chen H., Xiong S., Chi H., Xu W. A nuclear lncRNA Linc00839 as a Myc target to promote breast cancer chemoresistance via PI3K/AKT signaling pathway. Cancer Sci. 2020;111:3279–3291. doi: 10.1111/cas.14555. PubMed DOI PMC

Sun W., Li J., Zhou L., Han J., Liu R., Zhang H., Ning T., Gao Z., Liu B., Chen X., et al. The c-Myc/miR-27b-3p/ATG10 regulatory axis regulates chemoresistance in colorectal cancer. Theranostics. 2020;10:1981–1996. doi: 10.7150/thno.37621. PubMed DOI PMC

Meng Y., Wang L., Chen D., Chang Y., Zhang M., Xu J.-J., Zhou R., Zhang Q.-Y. LAPTM4B: An oncogene in various solid tumors and its functions. Oncogene. 2016;35:6359–6365. doi: 10.1038/onc.2016.189. PubMed DOI PMC

Li L., Wei X.H., Pan Y.P., Li H.C., Yang H., He Q.H., Pang Y., Shan Y., Xiong F.X., Shao G.Z., et al. LAPTM4B: A novel cancer-associated gene motivates multidrug resistance through efflux and activating PI3K/AKT signaling. Oncogene. 2010;29:5785–5795. doi: 10.1038/onc.2010.303. PubMed DOI

Xiong J., Wang L., Fei X.-C., Jiang X.-F., Zheng Z., Zhao Y., Wang C.-F., Li B., Chen S.-J., Janin A., et al. MYC is a positive regulator of choline metabolism and impedes mitophagy-dependent necroptosis in diffuse large B-cell lymphoma. Blood Cancer J. 2017;7:e582. doi: 10.1038/bcj.2017.61. PubMed DOI PMC